Type 2 Diabetes
Conditions
Interventions
Empagliflozin:Empagliflozin
intermittent fasting meal replacement:intermittent fasting meal replacement
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Enrolled in the previous EARLY study; after 16 weeks of intensive treatment in the EARLY study, the subjects whose glycated hemoglobin reached the target (<7%) and did not use hypoglycemic drugs are all subjects of this study.
Exclusion criteria
Exclusion criteria: Exclusion criteria: subjects not enrolled in the EARLY study; subjects enrolled in the EARYLY study, but not reaching the glycated hemoglobin target (>7%) after 16 weeks of intensive therapy; enrolled in the EARLY study and 16 weeks of intensive therapy Post-glycated hemoglobin has reached the target (<7%) but subsequent use of drugs that affect blood sugar and body weight (any hypoglycemic drugs, glucocorticoids, orlistat, etc.); compliance in the EARLY study is less than 80%, after the study Those who were judged as non-compliant subjects; women of childbearing age who had pregnancy, breastfeeding, etc.; those who had severe acute and chronic complications of diabetes within 6 months before screening (including lactic acidosis, non-ketotic hyperosmolarity coma, diabetic ketoacidosis, myocardial infarction, cerebrovascular accident, congestive heart failure, blindness due to diabetic retinopathy, renal failure and severe foot ulcers, etc.).
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| weight;blood sugar;blood pressure;blood lipid; | — |
Primary
| Measure | Time frame |
|---|---|
| Diabetes remission rate; | — |
Countries
China
Contacts
Public ContactLixin Guo
Outcome results
None listed